Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report

Suluck Soontaros , Supaporn Wongduang , Nattawut Leelakanok
{"title":"Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report","authors":"Suluck Soontaros ,&nbsp;Supaporn Wongduang ,&nbsp;Nattawut Leelakanok","doi":"10.1016/j.cpccr.2024.100328","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy.</div></div><div><h3>Case presentation</h3><div>We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim.</div></div><div><h3>Conclusion</h3><div>The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100328"},"PeriodicalIF":0.2000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy.

Case presentation

We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim.

Conclusion

The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化疗当天服用非格司亭预防药物引发过敏性休克:病例报告
导言:为预防发热性中性粒细胞减少症,建议在最后一次化疗后24-72小时使用非格司亭。我们接诊了一名右卵巢IIIC级未成熟畸胎瘤患者,她接受了BEP方案治疗。为了预防发热性中性粒细胞减少症,她在每个BEP周期接受了10剂filgrastim治疗。在第一个 BEP 周期,第一剂菲格拉司汀是在最后一次化疗用药后 24 小时内使用的,结果出现了呼吸困难。在第二周期的BEP治疗中,菲格司汀仍作为当天的治疗方案使用。第一次使用非格司亭一小时后,过敏性休克发生,患者接受了适当治疗。第二剂菲格拉司汀可成功再注射,菲格拉司汀可在无任何不良反应的情况下用完。在第三和第四个 BEP 周期中,菲格司汀被用作次日用药(间隔时间超过 24 小时)。结论在本例患者中,残余化疗可能会通过非IgE介导的机制增加非格司亭诱发过敏性休克的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
期刊最新文献
Acquired lipodystrophy following use of pembrolizumab Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report Refractory chronic lymphocytic leukemia with concomitant extramedullary multiple myeloma with lymph node involvement Adeno-squamous carcinoma of bartholin gland: Challenges in diagnosis and management of a less known vulvar cancer – A case report Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1